WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · HB 174

Legislative bill overview

HB 174 relates to the regulation and use of undesignated glucagon, a medication used to treat severe hypoglycemia (dangerously low blood sugar). The bill appears to establish or modify provisions allowing broader access to glucagon without requiring it to be specifically prescribed for an individual patient, similar to how automated external defibrillators (AEDs) are made widely available in public spaces.

Why is this important

Glucagon is a life-saving emergency medication, and expanding access could reduce deaths and serious injuries from untreated severe hypoglycemia, particularly among people with diabetes. Undesignated glucagon programs have been shown in other states to increase survival rates when bystanders can administer the drug quickly before emergency services arrive.

Potential points of contention

  • Liability concerns: Whether entities stocking undesignated glucagon face legal liability if administration causes harm or if someone uses it incorrectly
  • Training and access balance: Questions about what training requirements (if any) should apply versus keeping access simple enough for untrained bystanders to use in emergencies
  • Public health equity: Ensuring undesignated glucagon reaches underserved communities rather than concentrating only in wealthy areas with more resources

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.